Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)

• Published in: Journal of veterinary cardiology 2015-12, Vol.17, p.S306-S317
• Main Authors: Hogan, Daniel F., Fox, Philip R., Jacob, Kristin, Keene, Bruce, Laste, Nancy J., Rosenthal, Steven, Sederquist, Kimberly, Weng, Hsin-Yi
• Format: Article
• Language: English
• Subjects: Animals; Antithrombotics; Aspirin - adverse effects; Aspirin - therapeutic use; Cardioembolic; Cat Diseases - prevention & control; Cats; Double-Blind Method; Infarction; Male; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Thromboembolism - prevention & control; Thromboembolism - veterinary; Thromboprophylaxis; Thrombosis; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use
• ISSN: 1760-2734; 1875-0834
• DOI: 10.1016/j.jvc.2015.10.004

To determine if clopidogrel administration is associated with a reduced likelihood of recurrent cardiogenic arterial thromboembolism (CATE) in cats compared to aspirin administration. Secondary aims were to determine if clopidogrel administration had an effect on the composite endpoint of recurrent CATE and cardiac death and to identify adverse effects of chronic clopidogrel or aspirin therapy. Seventy-five cats that survived a CATE event. Multicenter, double-blind, randomized, positive-controlled study. Cats were assigned to clopidogrel (18.75 mg/cat PO q 24 h) or aspirin (81 mg/cat PO q 72 h). Kaplan–Meier survival curves were created for each endpoint and the log rank test performed to compare treatment groups with respect to time to event and the likelihood of the event occurring. The mean age of all cats was 8.0 ± 3.5 yr and 57/75 (76%) were male (p